Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2011-02-22
2011-02-22
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S443000
Reexamination Certificate
active
07893107
ABSTRACT:
Methods are provided directed to administering a therapeutically effective amount of a prostaglandin EP4agonist component to a mammal afflicted with or prone to afflicted with a disease or condition selected from an esophageal ulcer, alcohol gastropathy, a duodenal ulcer, non-steroidal anti-inflammatory drug-induced gastropathy, non-steroidal anti-inflammatory drug-induced enteropathy and intestinal ischemia. Such administration results in treating the disease or condition.
REFERENCES:
patent: 3931297 (1976-01-01), Crabbe
patent: 4117014 (1978-09-01), Pernet et al.
patent: 4171375 (1979-10-01), Caton et al.
patent: 6410591 (2002-06-01), Burk et al.
patent: 6538018 (2003-03-01), Burk et al.
patent: 6552067 (2003-04-01), Cameron et al.
patent: 6586468 (2003-07-01), Maruyama et al.
patent: 6610719 (2003-08-01), Paralkar et al.
patent: 6670485 (2003-12-01), Burk et al.
patent: 6747037 (2004-06-01), Old et al.
patent: 6747054 (2004-06-01), Cameron et al.
patent: 6875787 (2005-04-01), Donde
patent: 2003/0120079 (2003-06-01), Elworthy et al.
patent: 2003/0207925 (2003-11-01), Cameron et al.
patent: 2004/0142969 (2004-07-01), Elworthy
patent: 2004/0157901 (2004-08-01), Donde
patent: 2005/0020686 (2005-01-01), Maruyama et al.
patent: 2005/0124577 (2005-06-01), Tani et al.
patent: 850348 (1977-07-01), None
patent: 2701455 (1977-01-01), None
patent: 2752523 (1978-06-01), None
patent: 409167 (1975-11-01), None
patent: 2162213 (1972-12-01), None
patent: 2338244 (1977-01-01), None
patent: 2408567 (1978-11-01), None
patent: 1405301 (1975-11-01), None
patent: 52-097144 (1977-07-01), None
patent: 53-065854 (1978-06-01), None
patent: 63002972 (1988-01-01), None
patent: 7700272 (1977-01-01), None
patent: 7700257 (1977-07-01), None
patent: WO02/24647 (2002-03-01), None
patent: WO02/42268 (2002-05-01), None
patent: WO03/008377 (2003-01-01), None
patent: WO 03/008377 (2003-01-01), None
patent: WO03/009872 (2003-02-01), None
patent: WO 03/035064 (2003-05-01), None
patent: WO03/053923 (2003-07-01), None
patent: WO 03/053923 (2003-07-01), None
patent: WO03/074483 (2003-09-01), None
patent: WO03/077910 (2003-09-01), None
patent: WO03/103604 (2003-12-01), None
patent: WO 03/103604 (2003-12-01), None
patent: WO03/103664 (2003-12-01), None
patent: WO 03/103664 (2003-12-01), None
patent: WO 2004/019938 (2004-03-01), None
patent: WO 2004/037786 (2004-05-01), None
patent: WO 2004/037813 (2004-05-01), None
patent: WO 2004/065365 (2004-08-01), None
patent: WO 2004/078103 (2004-09-01), None
Fries et al., Arthritis & Rheumatism, 50/8 (Aug. 2004), pp. 2433-2440.
Friend and Chang, “A Colon-Specific Drug-Delivery System Based on Drug Glycosides and the Glycosidases of Colonic Bacteria”,J. Med. Chem. 1984, 27, 261-266.
Friend and Chang, “Drug Glycosides: Potential Prodrugs for Colon-Specific Drug Delivery”,J. Med. Chem. 1985, 28, 51-57.
Haeberlin et. al., “In Vitro Evaluation of Dexametnasone-β-D-Glucuronide for Colon-Specific Drug Delivery”,Pharmaceutical Research1993, 10, 1553-1562.
Hamon, A., et al., Synthesis of (+−)- and 15-EPI(+−)-10,10-Dimetnylprostaglandin E1,Tetrahedron Letters, Elsevier Science Publishers, Amsterdam, NL, No. 3, Jan. 1976, pp. 211-214.
Hirayama et al., “In-vitro Evaluation of Biphenyl Acetic Acid-β-Cyclodextrin Conjugates as Colon-targeting Prodrugs: Drug Release Behaviour in Rat Biological Media”,J. Pharm. Pharacol. 1996, 48, 27-31.
Kabashima, et. al., “The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut”,The Journal of Clinical Investigation, Apr. 2002, vol. 109, No. 7, 883-893.
McLeod et. al., “Synthesis and chemical stability of glucocorticoid-dextran esters: potential prodrugs for colon-specific delivery”,Int J. Pharm. 1993, 92, 105-114.
Nakamura et. al., Development of a Prodrug of Salicylic Acid, Salicylic Acid-L-alanine Conjugate, Utilizing Hydrolysis by Rabbit Intestinal Microorganisms,J. Pharm. Pharmacol. 1992, 44, 295-299.
Nakamura et. al., “Hydrolysis of salicylic acid-tyrosine and salicylic acid-methionine prodrugs in the rabbit”,Int. J. Pharm. 1992, 87, 59-66.
Northey, A., et al., “Cellular distribution of prostanoid EP receptors mRNA in the rat gastrointestinal tract”,Prostaglandins Other Lipid Mediat. Jul. 2000;62(2):145-56.
Pernet, Andre G. et al., Prostaglandin analogs modified at the 10 and 11 positions,Tetrahedron Letters, (41), 1979, pp. 3933-3936.
Pelletier S., et al., “Prostaglandin E(2) increases cyclic AMP and inhibits endothelin-1 production/secretion by guinea-pig tracheal epithelial cells through EP(4) receptors”,Br J Pharmacol. Mar. 2001;132(5):999-1008.
Planterna, Otto G. et al., Synthesis of(±)-10.10-dimethylprostaglandin E1methyl ester and its 15-epimer,Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-organic Chemistry (1972-1999), (3), 1978, pp. 304-308.
Plantema, O. G. et al., Synthesis of 10,10-dimethyiprostaglandins1,Tetrahedron Letters, No. 34: 1975, pp. 2945-2948, Pergamon Press. Printed in Great Britain.
Savla U., et al., “Prostaglandin E2regulates wound closure in airway epithelium”,Am. J. Physiol. Lung Cell Mol. Physiol., 2001:280(3):L421-431.
Takafuji, V., et al., “Prostanoid receptors in intestinal eptithelium: selective expression, function, and change with inflammation”,Prostaglandins Leukot Essent Fatt. Acids, 2000;63(4):223-35.
Tanaka et. al., “Synthesis of Doxorubicin-Cyclodextrin Conjugates”,Journal of Antibiotics1994, 47, 1025-1029.
Uekama et al., “6A-O-[4-Biphenylyl)acetyl]-α-,-β-, and—γ-cyclodextrins and 6A-Deoxy-6A-[[(4-biphenylyl)acetyl]amino]-α-, -β-, γ-cyclodextrins: Potential Prodrugs for Colon-Specific Delivery”,J. Med. Chem. 1997, 40, 2755-2761.
Houchen et al., “Prosurvival and antiapoptotic effects of PGE2in radiation injury are mediated by EP2receptor in intestine,” Am J Ph siol Gastrointest Liver Physiol 284: G490-G498, 2003.
Hamann, et al., “An Anti-CD33 Antibody-Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia,” Choide of Linker, Bioconjugate Chem. 2002,13, 40-46.
Plantema, et al., “Synthesis of 10, 10-Dimethylprostaglandins,” Tetrahedron Letters No. 34, 1975, 2945-29485, 28, 51-57.
Jiang, et al., “The Prevention of Colitis by E Prostanoid Receptor 4 Agonist Through Enhancement of Epithelium Survival and Regeneration,” The Jornal of Pharmacology, 2007, 320:22-28.
Jiang, et al., “The Prevention of Colitis by E Prostanoid Receptor 4 Agonist Through Enhacement of Epithelium Survival and Regeneration,” The Journal of Pharmacology, 2007, 320:22-28, 2007.
Im Wha Bin
Jiang Guang-Liang
Wheeler Larry A.
Allergan Inc.
Ene Doina G.
Forrestal Kevin J.
Spivack Phyllis G.
Wurst John E.
LandOfFree
Therapeutic methods using prostaglandin EP 4 agonist... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic methods using prostaglandin EP 4 agonist..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic methods using prostaglandin EP 4 agonist... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2645579